CADPS anticorps (N-Term)
Aperçu rapide pour CADPS anticorps (N-Term) (ABIN6990891)
Antigène
Voir toutes CADPS AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- AA 90-140, N-Term
-
Specificité
- Numerous isoforms of CAPS1 are known to exist. This CAPS1 antibody is predicted to be specific to CAPS1 and not recognize CAPS2.
-
Purification
- CAPS1 Antibody is affinity chromatography purified via peptide column.
-
Immunogène
- CAPS1 antibody was raised against a 21 amino acid synthetic peptide near the amino terminus of the human CAPS1. The immunogen is located within amino acids 90 - 140 of CAPS1.
-
Isotype
- IgG
-
-
-
-
Indications d'application
-
CAPS1 antibody can be used for detection of CAPS1 by Western blot at 0.25 - 0.5 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 5 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in rat samples, Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested. -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 mg/mL
-
Buffer
- CAPS1 Antibody is supplied in PBS containing 0.02 % sodium azide.
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- -20 °C,4 °C
-
Stockage commentaire
- CAPS1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
-
-
- CADPS (Ca++-Dependent Secretion Activator (CADPS))
-
Autre désignation
- CAPS1
-
Sujet
- CAPS1 Antibody: CAPS1 and its related protein CAPS2 encode novel neural/endocrine-specific cytosolic and peripheral membrane proteins. Both are essential components of the synaptic vesicle priming machinery and are required for the Ca2+-regulated exocytosis of secretory vesicles, CAPS-deficienct neurons contain no or very few fusion competent synaptic vesicles, causing a selective impairment of fast phasic transmitter release. CAPS1 acts at a stage in exocytosis that follows ATP-dependent priming, which involves the essential synthesis of phosphatidylinositol 4, 5-bisphosphate and is thought to be a specific regulator of large dense-core vesicle fusion.
-
ID gène
- 8618
-
NCBI Accession
- NP_899631
-
UniProt
- Q9ULU8
-
Pathways
- Synaptic Vesicle Exocytosis
Antigène
-